Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
US-2024336624-A1 · Oct 10, 2024 · US
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8993632B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993632-B2 |
| Application number | US-201213469021-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 10, 2012 |
| Priority date | Jan 5, 2005 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a patient suffering from a disorder selected from the group consisting of neuropathy, neuronal dysfunction, decline in cognitive function in Alzheimer's disease and associated dementias, attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), mild cognitive impairment, steroid-induced acute psychosis, schizophrenia, and combinations thereof, comprising administering to the patient an effective amount of a…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993632B2 cover?
- The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
- Who is the assignee on this patent?
- Bitner R Scott, Browman Kaitlin E, Brune Michael E, and 15 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/498. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).